Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
SPPI - is anyone expecting any sigificant movement with SPPI's earnings tomorrow? I know the bigger picture is April 29 but I'm wondering if earnings due poorly or suprise will it move the stock much?
NEOP - How much more room does NEOP have to grow? Does anyone think it will be a sell on news event when they announce phase 3 since it's increased it's value a lot over the past few months?
PLX - from their 10K filed today:
"In February 2010, the Israeli MOH completed a successful good manufacturing practices (GMP) audit of our manufacturing facilities in
Carmiel, Israel. The audit was performed as part of the Israeli MOH's evaluation of our manufacturing process for taliglucerase alfa. On
February 20, 2011, we received a letter from the FDA notifying us that the FDA had completed its review of the Establishment Inspection Report in
connection with the FDA's inspection of our facility in Carmiel, Israel, and that the FDA had classified our facility as acceptable."
I think this is very positive for PLX.
I think with PLX it's different though because the volume is low and it's not as dramatic of a decrease that DEPO saw during the regular hours.
PLX - odds of a bear raid?
Anyone have any thoughts on this? I will be keeping cash ready just in case but I don't believe we'll see one for PLX.
UBS just downgraded them to Neutral hence the drop. Nice timing on your exit. I still think there is plenty of room to go up once they are approved though.
pcrutch were you short on OREX? I think I remember previously around the panel decision you were but didn't remember if you pulled your position.
I had no position in OREX. Sorry for those that did :(
Next up I think for me is PLX and HGSI. I still need to do more DD on PLX though.
Yup a few lucky people got in around the 17's! Some good plays thus far this year.
Yeah but CLDA halted their stock til Monday...I'm worried it won't trade with as much hype but I still think it will be a great day either way :)
Congrats all! I was hoping for a halt till Monday but I'll take the approval :)
Good work on DD people. Monday should be a fun day.
There weren't enough shorts in DEPO for a bear raid + given the abbott news that provided a low entry to begin with too.
I hope we hear after hours but are halted till Monday :)
DEPO isn't a heavily shorted stock like some of the other bear raided stocks we typically have seen (POZN, AVNR, DNDN etc.) and the fact that they had news that brought the share price down pretty low already makes me think we won't see one.
But I will probably put a few orders in just in case it does happen :)
I still think we're in a good position. Sure there is some uncertainty but based on the conference call I'm pretty confident they will do whats best for their shareholders.
Also I still think we can see a bump in SP on approval so I don't think it's a lost cause and they certaintly have other things in their pipeline.
I'm not sure we'll see 10 like some people were predicting upon approval but I wouldn't be surprised to see 7-9 if approved. Roth still holds their $9 target.
Aastrom Receives Key U.S. Composition of Matter Patent for Autologous Cell Therapy
01/18 08:30 AM
ANN ARBOR, Mich., Jan. 18, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (ASTM:$3.08,00$-0.05,00-1.60%) , a leading developer of expanded autologous cellular therapies for severe, chronic cardiovascular diseases, today announced that it has been granted a U.S. patent which provides composition of matter protection for its investigational expanded autologous cell therapy product.
The issued patent, entitled Mixed Cell Populations for Tissue Repair and Separation Technique for Cell Processing, broadly covers "an isolated cell composition for tissue repair comprising a mixed population of cells of hematopoietic, mesenchymal and endothelial lineage." The company's patented single-pass perfusion technology enables the selective expansion of certain cell populations which have been shown to promote wound healing, new blood vessel formation and tissue restoration and address the underlying inflammation associated with CLI.
"This is a fundamental patent for Aastrom which expands our intellectual property estate and supports the basis for a proprietary cellular therapy product derived from our technology," said Tim Mayleben, president and CEO of Aastrom Biosciences (ASTM:$3.08,00$-0.05,00-1.60%) . "The patent establishes the novelty of our cell populations which we believe produce a greater combined therapeutic benefit than purified cell populations or freshly isolated bone marrow cells. We are pleased that the U.S. patent office now recognizes this cell mixture to be unique to Aastrom.
Aastrom's expanded autologous therapy is now in clinical trials for the treatment of critical limb ischemia (CLI) and dilated cardiomyopathy (DCM). In October 2010, the company announced that its planned Phase 3 clinical program in CLI received Fast Track designation by the U.S. Food and Drug Administration. The company also submitted documents to the FDA in support of special protocol assessments for the program.
Aastrom now has 26 U.S. and 36 foreign patents covering the composition, production and use of mixed-cell products.
About Aastrom Biosciences (ASTM:$3.08,00$-0.05,00-1.60%)
Aastrom Biosciences (ASTM:$3.08,00$-0.05,00-1.60%) is an emerging biotechnology company developing expanded autologous cellular therapies for use in the treatment of severe, chronic cardiovascular diseases. The company's proprietary cell-processing technology enables the manufacture of mixed-cell therapies expanded from a patient's own bone marrow and delivered directly to damaged tissues. Aastrom has advanced its cell therapies into late-stage clinical development, including a planned Phase 3 clinical program for the treatment of patients with critical limb ischemia and two ongoing Phase 2 clinical trials in patients with dilated cardiomyopathy.
For more information, please visit Aastrom's website at www.aastrom.com.
The Aastrom Biosciences, Inc. (ASTM:$3.08,00$-0.05,00-1.60%) logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3663
This document contains forward-looking statements, including without limitation, statements concerning our intellectual property, therapeutic benefits of cell populations, clinical trial plans and progress, objectives and expectations, clinical activity timing, intended product development, the performance and contribution of certain individuals and expected timing of collecting and analyzing treatment data, all of which involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such as "anticipates," "intends," "estimates," "plans," "expects," "we believe," "we intend," and similar words or phrases, or future or conditional verbs such as "will," "would," "should," "potential," "could," "may," or similar expressions. Actual results may differ significantly from the expectations contained in the forward-looking statements. Among the factors that may result in differences are the inherent uncertainties associated with clinical trial and product development activities, regulatory approval requirements, competitive developments, and the availability of resources and the allocation of resources among different potential uses. These and other significant factors are discussed in greater detail in Aastrom's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. These forward looking statements reflect management's current views and Aastrom does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release except as required by law.
CONTACT: Media contact
Agnes CaoBerry & Company
212 253-8881
acao@berrypr.com
Investor Contact
Scott DurbinAastrom Biosciences (ASTM:$3.08,00$-0.05,00-1.60%)
734 930-5777
ir@aastrom.com
Image: company logo
OT: Anyone else digging out? I'm still not even done but needed a break from the snow.
Settlement Date | Short Interest | Avg Daily Share Volume | Days To Cover
12/15/2010 | 3,056,143 | 2,728,368 | 1.120136
Read more: http://www.nasdaq.com/aspxcontent/shortinterests.aspx?symbol=astm&selected=astm#ixzz1AfloVZR3
The last reading on nasdaq was 3mil short
Nice. It'd be nice if we could see another repeat run of what we saw in November!
Nice play on the ASTM options pc! I'm liking ASTM this morning, hopefully it keeps going through the afternoon.
Should be interesting to see how it opens after coming out of the halt. I sold yesterday thinking it would be sell on news event but who knows. I'll be watching though in case an opportunity presents itself.
Good luck!
For those of you in RPC, are you planning on staying in for the potential news tomorrow? Or do you think it will sell on news?
I'd like to believe it has more room left to run on the so called naked shorts (30-40mil+ apparently, not sure how accurate that is).
Most likely we'll hear something tomorrow. I think we still can breakout today.
Yeah great call! I'm a little late to the game at .80 but the last time RPC ran it went from .30's to 2.50's...not saying it's going to happen again but there is interest gaining in this stock.
Nice...I sold mine at 4 today earlier in PM...
Then I thought I made the right move but it definitely is showing strength! Good hold.
I'm happy with the profit though, it's helped offset some of my recent losses with CYTK.
Well I think it will be positive news.
AH is reacting in a positive manner too, so I hope you make some $$! Kind of wished I kept a little bit now...
I sold earlier today at 4.28, guess we'll see if I made the right decision. My guess results are positive but I'm not sure what the share price will do since the stock has gone up a lot this year already.
INHX - had a strong finish...I was watching this one earlier today
Color, that was one trade probably settling from earlier in the day or a short attempting to scare longs.
I think XOMA will continue to go up tomorrow in the morning then start to settle down.
Can't deny that their management has been crap...maybe there is a leak about the CEO being fired :)
All jokes aside, I'm still curious if something did leak such as partner, buyout, etc.
pc, it's not even back at the level before the r/s...plus with the the summer street report saying they believe positive phase 2 results coming in jan...
edit:
link:
http://www.bizjournals.com/sanfrancisco/news/2010/12/21/xoma-shares-rocket-on-research-report.html?ana=yfcpc
That is the o/s...that's after the r/s
baggers,
Nice call on XOMA...where do you see this one landing once all is said and done?
It seems like this one could be a multi-day run given the volume.
Thoughts?
pcrutch, another big buy today for CORT 250k @ 4.20
15:42:02 $ 4.20 250,000
Big $$$ is coming in, so it seems...
CORT: Someone bought 500K @ 4.12 today...
I was expecting a nice jump with the good news but it looks like so far it's not going to do that.
I'm also surprised there hasn't been more pre-market action.
My guess is people not wanting to miss something over the weekend. I picked up a little more today at 1.84.
Amen.
I was going to reply with something similar but didn't bother. Thanks for replying to him!
CYCCP shot up 11% :)
Aastrom Presents Positive Second Interim Analysis of Phase 2b RESTORE-CLI Clinical Trial
http://finance.yahoo.com/news/Aastrom-Presents-Positive-pz-2208556570.html?x=0&.v=1
I've sold half and now have free shares too. I really was expecting an higher PPS out of this one, hopefully we get another rally today to push it past 6+.